BioSpace News Archive

SYNAPS Dx (SDx) today appointed an accomplished group of physicians, neuroscientists and esteemed leaders in neurodegenerative disease to its newly formed Scientific Advisory Board (SAB), reinforcing its commitment and position as an innovator and first-mover in the AD diagnostics industry.

Transformational year highlighted by record surgical volume, record growth, and publication of Level 1 clinical evidence

eClinical Solutions today announced the results from its 2024 Industry Outlook, an annual report synthesizing research with 77 professionals working across clinical operations, data management, statistical programming, and biometrics functions to reveal insights on the most pressing trends, challenges, and opportunities shaping the clinical data landscape.

Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company focused on the development of a new class of targeted therapies, N-myristoyltransferase inhibitors (NMTi) for the treatment of hematologic and solid tumor cancers.

Starton Therapeutics Inc. (“Starton” or the “Company”) announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for Solid State Active Pharmaceutical Composition for Transdermal Drug Delivery, referred to by the Company as STARTICLES.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced, in anticipation of upcoming investor meetings, its strategic priorities for 2024.

Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest.

Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al. in the International Journal of Cancer which summarizes the efficacy and safety of anti-GD2 monoclonal antibodies (mAbs) (dinutuximab, dinutuximab beta, and naxitamab) in children with high-risk neuroblastoma.

Amplia Therapeutics Limited, is pleased to announce that the US FDA have cleared Amplia’s IND application for a trial of Amplia’s best-in-class focal adhesion kinase inhibitor narmafotinib in pancreatic cancer.

AlzeCure Pharma AB announced that Anna Tenje, Minister for Older People and Social Security, together with representatives from the government and the Swedish Alzheimer’s Foundation, on Wednesday 17 January visited AlzeCure Pharma.